The company focuses on creating products that prevent antibiotic resistance, antibiotic-associated diarrhea, and hospital associated infections. Their offerings include a bioengineered enzyme that removes excess harmful antibiotics in the intestine and maintains a normal intestinal microflora. Ipsat Therapies also develops various antibiotics such as penicillin, cephalosporin, carbapenems, and fixed combination products. Founded in 1999 and based in Helsinki, Finland, Ipsat Therapies is dedicated to improving antibiotic treatment outcomes.